文献速递心力衰竭与心肌病

达格列净用于近期因心衰住院且射血分数轻度降低或保留的患者

Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction.
PubMed 文献 · J Am Coll Cardiol · 2022-08-27

DELIVER 试验预设分析纳入 6263 例 LVEF>40% 的心衰患者,其中 654 例(10.4%)在住院期间或出院 30 天内随机。近期心衰住院者主要结局风险更高(HR 1.88),达格列净在近期住院者中降低主要结局 22%(HR 0.78),非近期住院者降低 18%(HR 0.82),交互作用 P=0.71;不良反应相似。

要点

  • 近期因心衰住院患者主要结局风险显著升高(HR 1.88)。
  • 达格列净在近期住院与非近期住院患者中疗效一致(交互 P=0.71)。
  • 近期住院患者使用达格列净不良事件与安慰剂相似。

核心结论

  • 达格列净在近期住院与非近期住院的射血分数轻度降低或保留心衰患者中相似地降低心衰恶化或心血管死亡风险。
  • 在近期心衰住院期间或出院后 shortly 启动达格列净看似安全有效。

研究设计与样本

  • DELIVER 试验预设分析,随机对照试验。
  • 纳入 6263 例 LVEF>40% 的心衰患者,随机接受达格列净或安慰剂。
  • 654 例(10.4%)在因心衰住院期间或出院 30 天内随机。

主要发现

  • 近期心衰住院与主要结局风险升高相关(多变量校正 HR 1.88;95%CI 1.60-2.21;P<0.001)。
  • 达格列净在近期住院患者中降低主要结局 22%(HR 0.78;95%CI 0.60-1.03)。
  • 达格列净在非近期住院患者中降低主要结局 18%(HR 0.82;95%CI 0.72-0.94;Pinteraction=0.71)。
  • 近期住院患者中容量不足、糖尿病酮症酸中毒或肾脏事件等不良事件发生率在达格列净与安慰剂间相似。

临床怎么用

  • 对 LVEF>40% 且近期因心衰住院的临床稳定患者,可考虑在住院期间或出院后 shortly 启动达格列净。
  • 启动达格列净时需关注容量不足、糖尿病酮症酸中毒及肾脏事件,但近期住院患者中这些事件与安慰剂相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients recently hospitalized for heart failure (HF) are at high risk for rehospitalization and death. OBJECTIVES: The purpose of this study was to investigate clinical outcomes and response to dapagliflozin in patients with HF with mildly reduced or preserved left ventricular ejection fraction (LVEF) who were enrolled during or following hospitalization. METHODS: The DELIVER (Dapagliflozin Evaluation to Improve the LIVES of Patients With PReserved Ejection Fraction Heart Failure) trial randomized patients with HF and LVEF >40% to dapagliflozin or placebo. DELIVER permitted randomization during or shortly after hospitalization for HF in clinically stable patients off intravenous HF therapies. This prespecified analysis investigated whether recent HF hospitalization modified risk of clinical events or response to dapagliflozin. The primary outcome was worsening HF event or cardiovascular death. RESULTS: Of 6,263 patients in DELIVER, 654 (10.4%) were randomized during HF hospitalization or within 30 days of discharge. Recent HF hospitalization was associated with greater risk of the primary outcome after multivariable adjustment (HR: 1.88; 95% CI: 1.60-2.21; P < 0.001). Dapagliflozin reduced the primary outcome by 22% in recently hospitalized patients (HR: 0.78; 95% CI: 0.60-1.03) and 18% in patients without recent hospitalization (HR: 0.82; 95% CI: 0.72-0.94; Pinteraction = 0.71). Rates of adverse events, including volume depletion, diabetic ketoacidosis, or renal events, were similar with dapagliflozin and placebo in recently hospitalized patients. CONCLUSIONS: Dapagliflozin safely reduced risk of worsening HF or cardiovascular death similarly in patients with and without history of recent HF hospitalization. Starting dapagliflozin during or shortly after HF hospitalization in patients with mildly reduced or preserved LVEF appears safe and effective. (Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure [DELIVER]; NCT03619213).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Cunningham, Vaduganathan, Claggett, et al. Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction. J Am Coll Cardiol. 2022. PMID: 36041912. doi:10.1016/j.jacc.2022.07.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。